Pomalidomide plus chemotherapy for HIV-related lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can sign written informed consent.
- You have confirmed B-cell non-Hodgkin lymphoma, and it includes one of these: fluid/meninges involvement, high risk to relapse in the brain, plasmablastic type, tumor positive for gamma herpesvirus, or presence of Kaposi sarcoma (KS).
- You have HIV infection (HIV-1 or HIV-2) and are willing to take and stick to HIV treatment (ART).
- You haven’t had prior “curative-intent” chemotherapy for lymphoma (with limited exceptions if chemo was given briefly before curative treatment).
- Your scans or tests show lymphoma you can measure or assess, and you meet key blood, liver, and kidney function thresholds.
- If you can become pregnant, you must take pregnancy tests and use two reliable birth-control methods or commit to abstinence, starting before treatment; if you can father a child, you must use effective contraception and you can’t donate/freeze sperm during the study period.
- You must be able to safely take aspirin daily (or an approved alternative) and agree to a special pomalidomide risk-management program (REMS).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab combined with standard chemoimmunotherapy (called R-CHOP) for people with HIV-related large B-cell lymphoma that has not been treated before. The goal is to see if adding this drug improves outcomes and is safe.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
This Phase 2 trial tests whether adding targeted immunotherapy to standard chemotherapy and radiation can improve outcomes in children with certain types of lymphoma. It may help the immune system work better against cancer.
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
This trial tests two drugs (pomalidomide and nivolumab) in people with cancers caused by viruses. The goal is to see if this combination can shrink or control tumors that haven't responded to standard therapies.
This study looks at using two drugs, pomalidomide and rituximab, as maintenance therapy after initial treatment for younger adults with a high-risk type of non-Hodgkin lymphoma called DLBCL. The goal is to see if this combination helps keep the cancer in remission longer.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.